First Surgical Implant of ZIP ULTRA™ MIS Interspinous Device Performed in the United Kingdom
Aurora Spine Corporation (TSX VENTURE:ASG) announced today the first surgical implant of the company's ZIP ULTRA™ Minimally Invasive Interspinous Device in the United Kingdom. The surgery was performed at the University Hospital Llandough, a part of the Cardiff and Vale University Health Board, by Mr. Stuart James.
"The ZIP MIS implant is very well designed. It is both stable and secure. Implanting the device was simple, easy and safe," said Mr. Stuart James. "I will be expanding my use of the product as I believe it has multiple spine fusion indications."
Mr. James has completed a recognized spine fellowship in Bristol, UK, where he has gained extensive experience in all aspects of spinal disease and spinal conditions. His experience ranges from trauma and tumor work through to adult and pediatric complex deformity of the spine. In addition to his spine specialist training in the UK, Mr. James has gained further exposure and training in cutting edge contemporary spinal techniques across Europe and the USA.
"We are absolutely thrilled that Aurora now offers our MIS portfolio in the United Kingdom, including the ZIP MIS Interspinous System. We believe that the ZIP device will change spine surgery in the U.S. with a true minimally invasive approach designed to achieve reproducible, superior patient outcomes," said Trent Northcutt, President and Chief Executive Officer. "We are eager to introduce the ZIP across the U.K., and to drive the shift toward minimally invasive techniques. Our initial reception in the UK has been fantastic, and we want to thank Mr. James for his support of the Aurora vision."
About Aurora Spine
Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the growth potential of the Aurora Spine's products. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
For more information, please contact:
Aurora Spine Corporation
President and Chief Executive Officer
Chief Financial Officer